Cytokine inhibitors:: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet's disease

被引:52
作者
Düzgün, N
Ayaslioglu, E
Tutkak, H
Aydintug, OT
机构
[1] Ankara Univ, Sch Med, Dept Internal Med Clin Immunol & Rheumatol, TR-06100 Ankara, Turkey
[2] Kirikkale Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Kirikkale, Turkey
关键词
Behcet's disease; interleukin-1; interleukin-1 receptor antagonist; soluble tumor; necrosis factor receptor 1; tumor necrosis factor;
D O I
10.1007/s00296-003-0400-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Serum levels of proinflammatory cytokines interleukin-1 beta (IL-1beta), tumor necrosis factor alpha, (TNF-alpha), and their inhibitors, IL-1 receptor antagonist (IL-1ra) and soluble TNF receptor 1 (sTNFR1), were determined by enzyme-linked immunosorbent assay in 104 patients with Behcet's disease (65 active, 39 inactive) and 40 healthy controls. The levels of IL-1beta and IL-1ra were significantly higher in both active and inactive patients than in control subjects (P < 0.01 and P < 0.01, respectively). The concentrations of TNF-alpha and sTNFR1 were found to be higher in active patients than in controls (P < 0.01 and P < 0.001, respectively). There were no significant differences in the serum levels of these cytokines and their inhibitors between active and inactive patients. Significant increases in mean C-reactive protein level and erythrocyte sedimentation rate were found in patients with active vs inactive disease (P < 0.001 and P < 0.05, respectively). C-reactive protein values correlated with erythrocyte sedimentation rate but not with cytokines or their inhibitors. Our conclusion is that elevated serum TNF-alpha and sTNFR1 seem to be important inflammatory mediators in Behcet's disease. The statistically significant increase in these levels may arise from the severity of inflammation in the tissue or organ involved.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 30 条
[11]   Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease [J].
Evereklioglu, C ;
Er, H ;
Türköz, Y ;
Çekmen, M .
MEDIATORS OF INFLAMMATION, 2002, 11 (02) :87-93
[12]   SYNOVIAL INTERLEUKIN-1 RECEPTOR ANTAGONIST AND INTERLEUKIN-1 BALANCE IN RHEUMATOID-ARTHRITIS [J].
FIRESTEIN, GS ;
BOYLE, DL ;
YU, C ;
PAINE, MM ;
WHISENAND, TD ;
ZVAIFLER, NJ ;
AREND, WP .
ARTHRITIS AND RHEUMATISM, 1994, 37 (05) :644-652
[13]  
Freysdottir J, 1999, CLIN EXP IMMUNOL, V118, P451
[14]   ELEVATED SERUM LEVELS OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN POLYMYOSITIS/DERMATOMYOSITIS - A BIOLOGIC MARKER OF DISEASE-ACTIVITY WITH A POSSIBLE ROLE IN THE LACK OF ACUTE-PHASE PROTEIN RESPONSE [J].
GABAY, C ;
GAYCROISIER, F ;
ROUXLOMBARD, P ;
MEYER, O ;
MAINETI, C ;
GUERNE, PA ;
VISCHER, T ;
DAYER, JM .
ARTHRITIS AND RHEUMATISM, 1994, 37 (12) :1744-1751
[15]  
HAMZAOUI K, 1990, J RHEUMATOL, V17, P1428
[16]   Anti-MHC autoimmunity in Behcet's disease:: T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis [J].
Kurhan-Yavuz, S ;
Direskeneli, H ;
Bozkurt, N ;
Özyazgan, Y ;
Bavbek, T ;
Kazokoglu, H ;
Eksioglu-Demiralp, E ;
Wildner, G ;
Diedrichs-Möhring, M ;
Akoglu, T .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 120 (01) :162-166
[17]  
MEGE JL, 1993, J RHEUMATOL, V20, P1544
[18]  
MEMISOGLU H, 1991, INFL DIS TH, V8, P387
[19]   ENDOTOXIN-STIMULATED HUMAN MONOCYTE SECRETION OF INTERLEUKIN-1, TUMOR NECROSIS FACTOR-ALPHA, AND PROSTAGLANDIN-E2 SHOWS STABLE INTERINDIVIDUAL DIFFERENCES [J].
MOLVIG, J ;
BAEK, L ;
CHRISTENSEN, P ;
MANOGUE, KR ;
VLASSARA, H ;
PLATZ, P ;
NIELSEN, LS ;
SVEJGAARD, A ;
NERUP, J .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1988, 27 (06) :705-716
[20]  
Nasonov E L, 2001, Klin Med (Mosk), V79, P33